AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10705191
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water (calcium content ranging between 55 and 130 mg/l)
Trial: 9023787
Drug: Venlafaxine (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (375 mg/day for 10 days, then reduced to 150 mg/day)
Trial: 30790557
Drug: HABIT-ILE (hand-arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HABIT-ILE (hand-arm bimanual intensive therapy) delivered over 2 weeks
Trial: 30790557
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (mostly neurodevelopmental) delivered 1-5 times/week
Trial: 28379310
Drug: Left atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left atrial volume increase (per 5 mL increase)
Trial: 23493606
Drug: EE 20
RxNorm normalized name: AcidFree 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 20 µg/DRSP 3 mg (flexible extended regimen)
Trial: 23493606
Drug: EE 20
RxNorm normalized name: AcidFree 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 20 µg/DRSP 3 mg (conventional 28-day cyclic regimen)
Trial: 23493606
Drug: EE 20
RxNorm normalized name: AcidFree 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 20 µg/DRSP 3 mg (fixed extended regimen)
Trial: 17420364
Drug: Topical beta-adrenergic
RxNorm normalized name: Beta-HC Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical beta-adrenergic antagonists
Trial: 12467106
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg glucose
Trial: 9117888
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) infusion
Trial: 3025246
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (HS) infusion
Trial: 3025246
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (NS) infusion
Trial: 3025246
Drug: CRH administration
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH administration during saline infusions
Trial: 28296588
Drug: AppleMetS® (AMS),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AppleMetS® (AMS), 2 capsules a day for one month
Trial: 21435021
Drug: 0.06% retinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06% retinyl retinoate cream for 3 months
Trial: 20078381
Drug: 0.075% retinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075% retinol cream
Trial: 18339027
Drug: QFT-G 'In
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QFT-G 'In Tube' assay
Trial: 18339027
Drug: QFT-G 'In
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QFT-G 'In Tube' assay and TST
Trial: 16887890
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of disulfiram and naltrexone
Trial: 8608540
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy (HF) at doses of 64.8, 72, 76.8, or 81.6 Gy
Trial: 8608540
Drug: Accelerated hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionated radiation therapy (AHF) at doses of 48 or 54.4 Gy
Trial: 8608540
Drug: Carmustine (BCNU)
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine (BCNU) administered with both HF and AHF
Trial: 27618639
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (homework‐focused parent training and a daily report card; BPT + DRC)
Trial: 23380213
Drug: Chiropractic spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic spinal instrument-based manipulative treatments (9 treatments over 2 weeks)
Trial: 29983189
Drug: Standard ointment
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard ointment dressings
Trial: 25332325
Drug: Low-genistein (LG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-genistein (LG) supplement (100 mg isoflavones/d)
Trial: 25332325
Drug: High-genistein (HG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-genistein (HG) supplement (100 mg isoflavones/d)
Trial: 22378566
Drug: Golimumab (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab (combined 50 mg and 100 mg)
Trial: 10412878
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg daily for 16 weeks)
Trial: 10412878
Drug: Fosinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (20 mg daily for 16 weeks)
Trial: 7600840
Drug: Corticosteroids (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (low-dose vs. high-dose)
Trial: 2393268
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cefpodoxime proxetil (single dose)
Trial: 2393268
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cefpodoxime proxetil (steady state, after 5 days)
Trial: 2393268
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg cefpodoxime proxetil (single dose)
Trial: 2393268
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg cefpodoxime proxetil (steady state, after 5 days)
Trial: 2393268
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing regimens (200 mg and 400 mg)
Trial: 7290471
Drug: Silymarin (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (420 mg/die/os)
Trial: 25950503
Drug: Topical fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluorouracil cream, 5% (n=468)
Trial: 24053647
Drug: HTK with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTK with topical cooling
Trial: 24053647
Drug: HTK without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HTK without topical cooling
Trial: 21355946
Drug: Iyengar yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iyengar yoga practice (90 min twice weekly for 8 weeks)
Trial: 19787222
Drug: Estrogen receptor-beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen receptor-beta (ER-beta) expression
Trial: 17096171
Drug: Intraarticular 100
RxNorm normalized name: calcium chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular 100 mg of tramadol in 20 ml normal saline and periarticular incisional injection of 10 ml bupivacaine 0.5% (Group TB)
Trial: 17096171
Drug: Intraarticular 20
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular 20 ml 0.25% and periarticular incisional 10 ml 0.5% bupivacaine injections (Group BB)
Trial: 10726235
Drug: Trazodone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (mean once‐daily dose 111.5 +/- 36.3 mg)
Trial: 10726235
Drug: Clorazepate (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate (mean once‐daily dose 17.5 +/- 7.5 mg)
Trial: 2029287
Drug: Rectally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectally administered diazepam (R‐DZP)
Trial: 6459190
Drug: BCG treatments
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG treatments (all types)
Trial: 26262904
Drug: Short-acting oral
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting oral methylphenidate, taken two or three times daily; each dose ranged between 0.3 and 1.0 mg/kg.
Trial: 23218404
Drug: Bryophyllum pinnatum
RxNorm normalized name: Millettia pinnata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bryophyllum pinnatum (BP) 350 mg/day (3×2 capsules)
Trial: 12510801
Drug: Teriparatide treatment
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide treatment for a median of 19 months
Trial: 11072392
Drug: Coping-skills Relapse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping-skills Relapse Prevention (RP) treatment
Trial: 11072392
Drug: Health Belief
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health Belief Model (HBM) treatment
Trial: 7576392
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (including fluoride dentifrices)
Trial: 6776974
Drug: High-flow oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow oxygen therapy (2 litre min-1 oxygen and 13 litre min-1 air) for 30 min followed by low-flow oxygen therapy (2 litre min-1 dry oxygen) for 30 min
Trial: 6776974
Drug: Low-flow oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow oxygen therapy (2 litre min-1 dry oxygen) for 30 min followed by high-flow oxygen therapy (2 litre min-1 oxygen and 13 litre min-1 air) for 30 min
Trial: 30905130
Drug: Adjunctive 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive 1,000 mg/day of mangosteen pericarp
Trial: 22196196
Drug: Light extrusive
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light extrusive forces (25 g)
Trial: 22196196
Drug: Heavy extrusive
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy extrusive forces (225 g)
Trial: 21058477
Drug: Ibuprofen capsules
RxNorm normalized name: Diphenhydramine Hydrochloride and Ibuprofen Capsules
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen capsules for 30 days
Trial: 18186237
Drug: Inhaled bronchodilators
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilators
Trial: 15774170
Drug: Tight control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight control of blood glucose by intensive insulin therapy (maintenance of blood glucose at a level between 4.4 and 6.1 mmol/L)
Trial: 15774170
Drug: Tight control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight control of blood glucose by intensive insulin therapy
Trial: 15774170
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (maintenance of glucose at a level between 10.0 and 11.1 mmol/L)
Trial: 11821798
Drug: Hyperthermia combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermia combined with chemotherapy and radiotherapy
Trial: 11821798
Drug: Intra- or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra- or postoperative hyperthermia treatment
Trial: 11821798
Drug: Hyperthermia for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermia for unresectable or local recurrent rectal cancer
Trial: 7602364
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy for intermediate-grade lymphomas
Trial: 7602364
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy or therapy for low-grade lymphoma or Hodgkin's disease
Trial: 7602364
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy for intermediate-grade lymphoma
Trial: 7602364
Drug: Other therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other therapies (including salvage therapies)
Trial: 7602364
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy directed at large-cell lymphomas
Trial: 30870102
Drug: Single session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single session of Behavioural Activation followed by 8 weeks of daily SMS messages (INT)
Trial: 26275599
Drug: GentleWave System
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GentleWave System (GWS) treatment
Trial: 22729012
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (1.5 g mixed in 100 cc of saline)
Trial: 22729012
Drug: Intra-articular tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular tranexamic acid (1.5 g mixed in 100 cc of saline)
Trial: 22729012
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline administered into the knee joint cavity and intravenously)
Trial: 16005883
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and Simvastatin
Trial: 11725155
Drug: HRT 1
RxNorm normalized name: FEMHRT 1/5 TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT 1 (1 mg of 17beta‐oestradiol per day continuously plus 0.025 mg gestodene on days 17‐28 of each 4‐week cycle)
Trial: 11725155
Drug: HRT 2
RxNorm normalized name: EE/NETHDRONE (EQV-FEMHRT 2.5/0.5) TAB,28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT 2 (1 mg of 17beta‐oestradiol per day continuously plus gestodene in each third cycle only)
Trial: 9165186
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg fluoride daily in the form of a tablet
Trial: 3309479
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (one-dose protocol): All protamine infused within 10 minutes after termination of cardiopulmonary bypass.
Trial: 3309479
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (two-dose protocol): 75% of the calculated protamine dose infused within 10 minutes after termination of bypass, remainder after transfusion of all blood in the heart-lung machine.
Trial: 27228512
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 µg/kg (DEX I group)
Trial: 27228512
Drug: Dexmedetomidine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.3 µg/kg (DEX II group)
Trial: 27228512
Drug: Dexmedetomidine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.2 µg/kg (DEX III group)
Trial: 27228512
Drug: Meperidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 0.4 mg/kg (meperidine group)
Trial: 22353612
Drug: Antioxidant cocktail
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant cocktail (vitamin C, 1000 mg; vitamin E, 600 IU; α‐lipoic acid, 600 mg)
Trial: 18953651
Drug: Chemoendocrine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine treatment
Trial: 15842141
Drug: Aitongping capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aitongping capsule (ATP)
Trial: 12851275
Drug: Promensil (82
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promensil (82 mg of total isoflavones per day)
Trial: 12851275
Drug: Rimostil (57
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimostil (57 mg of total isoflavones per day)
Trial: 1746418
Drug: Oral controlled-release
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral controlled-release mononitrate for 1 month
Trial: 1746418
Drug: Oral captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral captopril for 1 month
Trial: 1746418
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium for 24 hours
Trial: 1746418
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for oral controlled-release mononitrate
Trial: 1746418
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for oral captopril
Trial: 1746418
Drug: Open control
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open control (no infusion) for intravenous magnesium
Trial: 6137945
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers (e.g., practolol, timolol, propranolol)
Trial: 6137945
Drug: Propranolol (Beta‐Blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (Beta‐Blocker Heart Attack Trial)
Trial: 30694523
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with neoadjuvant chemotherapy (NCT)
Trial: 26497831
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation providing 1400 mg per day EPA+DHA
Trial: 17465862
Drug: LT4/LT3 combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT4/LT3 combined therapy
Trial: 11487166
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of amoxicillin
Trial: 11487166
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of placebo control
Trial: 3294124
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with cimetidine 1 g daily and cisapride 40 mg daily
Trial: 3294124
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug therapy (cimetidine and placebo)
Trial: 3294124
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with cimetidine + cisapride
Trial: 21765368
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg once daily for 7 days with fimasartan 240 mg
Trial: 21765368
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg once daily for 7 days
Trial: 19835119
Drug: Warming needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming needling treatment combined with cupping (needle inserted on sciatic nerve at Huantiao (GB 30))
Trial: 19835119
Drug: Warming needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming needling treatment combined with cupping (needle not needled on sciatic nerve)
Trial: 11563999
Drug: Ibuprofen 2400
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 2400 mg daily
Trial: 9700954
Drug: Bombesin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bombesin infusion (1 ng/kg x min) during hyperglycemia
Trial: 7716349
Drug: Bamiphylline (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamiphylline (600 mg b.d. for 15 days)
Trial: 7716349
Drug: Placebo (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (600 mg b.d. for 15 days)
Trial: 9701388
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (i.v.Ig) prophylaxis
Trial: 8017316
Drug: Diltiazem CD
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem CD (DCD) 60 mg
Trial: 8017316
Drug: Diltiazem CD
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem CD (DCD) 120 mg
Trial: 8017316
Drug: Diltiazem CD
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem CD (DCD) 240 mg
Trial: 8017316
Drug: Diltiazem CD
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem CD (DCD) 360 mg
Trial: 8017316
Drug: Diltiazem CD
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem CD (DCD) 480 mg
Trial: 2400071
Drug: Guedel oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guedel oral airway
Trial: 71602
Drug: (−)‐deprenyl 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (−)‐deprenyl 10 mg daily or on alternate days